Oxalys Pharmaceuticals is a Toronto-based, early-stage MIT spin-off company developing small molecule therapeutics to address unmet medical needs in neurodegenerative diseases. Oxalys’ lead therapeutic, OXD-4, targets fundamental pathology behind cognitive decline and brain atrophy, and is on track for clinical trials in Huntington's disease patients in 2015.
CEO